HomeClinical TopicsCardio-PulmonaryFDA releases safety review update report for Benicar

FDA releases safety review update report for Benicar

As part of a safety review update on cardiovascular events and Benicar (olmesartan), the U.S. Food and Drug Administration states Benicar’s benefits “continue to outweigh its potential risks when used for the treatment of patients with high blood pressure according to the drug label http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=benicar&SearchType=BasicSearch. Read more at http://www.fda.gov/Drugs/DrugSafety/ucm251268.htm.


Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

covid-19 virus illustration

Will Omicron Be More Contagious Than Delta?

If the first thing you heard about the omicron variant over the holiday weekend was that it is bad news, the second thing was...